medcitynews.com
Open in
urlscan Pro
2606:4700:20::ac43:45a1
Public Scan
Submitted URL: http://go.pardot.com/e/710433/from-pfizer-into-pivotal-test-/czxq6/476391611?h=Lzoug7OIBnmwbMxlmKjPNNKHP3slKzr9IAZjPA...
Effective URL: https://medcitynews.com/2022/03/an2-therapeutics-ipo-raises-69m-to-take-antibiotic-from-pfizer-into-pivotal-test/
Submission: On March 28 via api from CH — Scanned from DE
Effective URL: https://medcitynews.com/2022/03/an2-therapeutics-ipo-raises-69m-to-take-antibiotic-from-pfizer-into-pivotal-test/
Submission: On March 28 via api from CH — Scanned from DE
Form analysis 6 forms found in the DOM
GET https://medcitynews.com/
<form method="get" class="search" action="https://medcitynews.com/" role="search">
<input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
<button type="submit"><i class="fa fa-search"></i></button>
</form>GET https://medcitynews.com/
<form method="get" class="search" action="https://medcitynews.com/" role="search">
<input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
<button type="submit"><i class="fa fa-search"></i></button>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" method="POST"
class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_b5e0cd58-f141-40f1-84a9-61df84d59740"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-0.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class=""
placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0.1:$0.0"><span data-reactid=".hbspt-forms-0.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-0.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class="hs-input" type="email" name="email" required=""
placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-0.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-0.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-0.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-0.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-0.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-0.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":1592.400001525879,"rumServiceResponseTime":1935.7999992370605,"rumFormRenderTime":2.3000030517578125,"rumTotalRenderTime":4144.900001525879,"rumTotalRequestTime":305.0999984741211,"embedAtTimestamp":"1648482681653","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/03/an2-therapeutics-ipo-raises-69m-to-take-antibiotic-from-pfizer-into-pivotal-test/","pageTitle":"AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test - MedCity News","source":"FormsNext-static-5.461","sourceName":"FormsNext","sourceVersion":"5.461","sourceVersionMajor":"5","sourceVersionMinor":"461","timestamp":1648482681656,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/99.0.4844.84 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#newsletter-form-mobile-interstitial","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial","renderedFieldsIds":["email"],"formTarget":"#newsletter-form-mobile-interstitial","correlationId":"6fea455a-fc07-4e30-8b25-4c86b62fdd90","hutk":"70c2269f2787880333093446e7be5a59","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-0.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" style="display:none;" data-reactid=".hbspt-forms-0.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data" id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983"
method="POST" class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_cf2603ec-393b-4bde-bf19-18a5a0298bac"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" data-reactid=".hbspt-forms-3">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-3.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983" class="" placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983"
data-reactid=".hbspt-forms-3.1:$0.0"><span data-reactid=".hbspt-forms-3.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-3.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
data-reactid=".hbspt-forms-3.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-3.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-3.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-3.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-3.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-3.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":1592.400001525879,"rumServiceResponseTime":4378.900001525879,"rumFormRenderTime":1.2999992370605469,"rumTotalRenderTime":4380.200000762939,"rumTotalRequestTime":186.70000076293945,"embedAtTimestamp":"1648482684177","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/03/an2-therapeutics-ipo-raises-69m-to-take-antibiotic-from-pfizer-into-pivotal-test/","pageTitle":"AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test - MedCity News","source":"FormsNext-static-5.461","sourceName":"FormsNext","sourceVersion":"5.461","sourceVersionMajor":"5","sourceVersionMinor":"461","timestamp":1648482684181,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/99.0.4844.84 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#signup-main-hubspot","redirectUrl":"http://medcitynews.com/youre-subscribed/"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","renderedFieldsIds":["email"],"formTarget":"#signup-main-hubspot","correlationId":"4fa4319e-c451-41dc-b2fa-420881854426","hutk":"70c2269f2787880333093446e7be5a59","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-3.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" style="display:none;" data-reactid=".hbspt-forms-3.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" method="POST"
class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_a3a6b12b-d8a1-4572-8e1e-0a9c97fdc212"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" data-reactid=".hbspt-forms-1">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-1.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" class="" placeholder="Enter your "
for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" data-reactid=".hbspt-forms-1.1:$0.0"><span data-reactid=".hbspt-forms-1.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-1.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" class="hs-input" type="email" name="email" required=""
placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-1.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-1.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-1.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-1.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-1.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-1.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":1592.400001525879,"rumServiceResponseTime":1936,"rumFormRenderTime":1.5999984741210938,"rumTotalRenderTime":4161.5,"rumTotalRequestTime":274.9000015258789,"embedAtTimestamp":"1648482681652","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/03/an2-therapeutics-ipo-raises-69m-to-take-antibiotic-from-pfizer-into-pivotal-test/","pageTitle":"AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test - MedCity News","source":"FormsNext-static-5.461","sourceName":"FormsNext","sourceVersion":"5.461","sourceVersionMajor":"5","sourceVersionMinor":"461","timestamp":1648482681656,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/99.0.4844.84 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#newsletter-form-sidebar","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-sidebar"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-sidebar","renderedFieldsIds":["email"],"formTarget":"#newsletter-form-sidebar","correlationId":"0a59553c-4a49-4530-b982-021e056dfb06","hutk":"70c2269f2787880333093446e7be5a59","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-1.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" style="display:none;" data-reactid=".hbspt-forms-1.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce" enctype="multipart/form-data" id="hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce"
method="POST" class="hs-form stacked hs-form-private hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce_5831121c-5aed-466a-87d1-c06832933b8e"
data-form-id="30083c7c-72db-412b-8a6e-e72e5b9308ce" data-portal-id="2097126" target="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" data-reactid=".hbspt-forms-2">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-2.1:$0"><label id="label-email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="" placeholder="Enter your " for="email-30083c7c-72db-412b-8a6e-e72e5b9308ce"
data-reactid=".hbspt-forms-2.1:$0.0"><span data-reactid=".hbspt-forms-2.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-2.1:$0.$email"><input id="email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
data-reactid=".hbspt-forms-2.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-2.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-2.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-2.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-2.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-2.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":1592.400001525879,"rumServiceResponseTime":4360,"rumFormRenderTime":2.0999984741210938,"rumTotalRenderTime":4362.299999237061,"rumTotalRequestTime":168.29999923706055,"embedAtTimestamp":"1648482684176","formDefinitionUpdatedAt":"1464813456785","pageUrl":"https://medcitynews.com/2022/03/an2-therapeutics-ipo-raises-69m-to-take-antibiotic-from-pfizer-into-pivotal-test/","pageTitle":"AN2 Therapeutics’ IPO raises $69M to take antibiotic from Pfizer into pivotal test - MedCity News","source":"FormsNext-static-5.461","sourceName":"FormsNext","sourceVersion":"5.461","sourceVersionMajor":"5","sourceVersionMinor":"461","timestamp":1648482684180,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/99.0.4844.84 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"30083c7c-72db-412b-8a6e-e72e5b9308ce","target":"#interstitial_hubspot","redirectUrl":"http://medcitynews.com/youre-subscribed/"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","renderedFieldsIds":["email"],"formTarget":"#interstitial_hubspot","correlationId":"0117f040-722a-44cc-bf0e-b40efefddfaa","hutk":"70c2269f2787880333093446e7be5a59","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-2.7"><iframe name="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" style="display:none;" data-reactid=".hbspt-forms-2.8"></iframe>
</form>Text Content
Menu Search * Home * News * Health Tech * Biopharma * Devices & Diagnostics * Consumer / Employer * Contributors * MedCity Influencers * MedCitizens * Events * Jobs * Research * Newsletters * About Us * Advertising * Contact us * Send Tips * Advertising * About * Twitter * Facebook * RSS * Subscribe via email X Close Signup Modal MEDCITY >> INBOX Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy. * Send Tips * Advertising * About * Twitter * Facebook * RSS * Subscribe via email MEDCITY NEWS SENATORS REQUEST GAO TO PROBLE MEDICAID’S LOW COVID VACCINATION RATES IBM DUMPING WATSON HEALTH IS AN OPPORTUNITY TO REEVALUATE ARTIFICIAL INTELLIGENCE ENVISION AIMS TO HELP VISUALLY IMPAIRED USERS LIVE INDEPENDENTLY WITH UPDATED AI-POWERED SMART GLASSES LESSONS LEARNED FROM FIGHTING HIV IN AFRICA—AND HOW THEY APPLY TO COVID-19 IN THE U.S. DATA AND REGULATORY ROUNDUP: PFIZER’S FEAT, AN ADHD MISS, ELI LILLY’S CRL & MORE 5 COMMON SOCIAL MEDIA MISTAKES IN HEALTH RESEARCH PARTICIPANT ENGAGEMENT PAIGE LAUNCHES SOFTWARE TO HELP DETECT BREAST CANCER THAT HAS SPREAD TO THE LYMPH NODES AN2 THERAPEUTICS’ IPO RAISES $69M TO TAKE ANTIBIOTIC FROM PFIZER INTO PIVOTAL TEST COVID ANTIVIRALS: HOW THE LAST MILE CAN SAVE THOSE AT HIGHEST-RISK HEARING IS BELIEVING IN CLINICAL TRIALS STARTUPDATES: NEW DEVELOPMENTS FROM HEALTHCARE STARTUPS PODIMETRICS SNAGS $45M TO GROW ITS DIABETIC FOOT HEALTH BUSINESS, PREVENT AMPUTATIONS LIGAND PHARMA TURNS TO A SPAC TO TAKE ANTIBODY BIZ PUBLIC, RAISE UP TO $266M EXPLORING THE NEXT CHAPTER OF INTEROPERABILITY CELSIUS THERAPEUTICS HEATS UP WITH $83M AND AN IBD DRUG ON PATH TO THE CLINIC * News * Health Tech * BioPharma * Devices & Diagnostics * Consumer / Employer * Contributors * MedCity Influencers * MedCitizens * Events * INVEST * INVEST PharmaTech * INVEST Digital Health * INVEST Population Health * Jobs * Research * Newsletters Don’t miss MedCity INVEST 2022 – March 28-30 at the Ritz-Carlton Chicago Pharma, BioPharma AN2 THERAPEUTICS’ IPO RAISES $69M TO TAKE ANTIBIOTIC FROM PFIZER INTO PIVOTAL TEST AN2 IS DEVELOPING AN ANTIBIOTIC BASED ON BORON CHEMISTRY THAT COULD OFFER ADVANTAGES OVER CARBON-BASED MOLECULES. THE BIOTECH PLANS TO ADVANCE ITS DRUG CANDIDATE, LICENSED FROM PFIZER, TO A PIVOTAL TEST IN A RARE AND POTENTIALLY FATAL LUNG INFECTION CAUSED BY MYCOBACTERIA. By Frank Vinluan Post a comment / Mar 25, 2022 at 12:40 PM 0Shares Economic concerns have halted or at least delayed the plans of many companies to go public, but one biotech is braving the financial tumult, raising $69 million from its IPO to fund a pivotal test of a novel antibiotic licensed from Pfizer. Promoted 3D PRINTED MEDICAL DEVICES FOR PRECISION SURGERY Formlabs is sponsoring a webinar exploring 3D printing from clinical, commercial, and regulatory perspectives. Join us on April 6th! Formlabs and MedCity News When AN2 Therapeutics set financial terms for the stock offering earlier this week, the company planned to offer 4 million shares in the range of $14 to $16 each. AN2 was able to boost the size of the deal to 4.6 million shares that priced Thursday night at the $15 per share midpoint. Those shares began trading on the Nasdaq Friday under the stock symbol “ANTX.” The biotech’s stock price opened at $16.85, up 12.3% from the IPO price. AN2’s lead drug candidate is its only drug. Epetraborole comes from Pfizer, which got the small molecule as part of its $5.2 billion acquisition of Anacor Pharmaceuticals in 2016. The key piece of that deal was Eucrisa, an atopic dermatitis drug that went on to win FDA approval but fell short of Pfizer’s blockbuster expectations. Both Eucrisa and Epetraborole are based on boron chemistry, which brings advantages in the ability to bind to and address biological targets that have been difficult to block using traditional carbon-based molecules. Epetraborole is designed to block an enzyme that’s key to bacteria, but is not addressed by other antibiotics. The approach is intended overcome the resistance that bacteria have developed other antibiotics. Anacor had advanced epetraborole to two Phase 2 tests with GlaxoSmithKline, a collaboration that was evaluating the drug in gram-negative infections. But early data showed signs of clinical resistance, which means the bacteria became less susceptible to the antibiotic. Those results led to the discontinuation of those studies. But AN2 noted in its prospectus that clinical resistance is possible for all antibiotics, and that risk can be mitigated with combination therapy. AN2 aims to test epetraborole in non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by mycobacteria. The condition leads to irreversible lung damage that can become fatal. NTM lung disease is currently treated with combination therapy, and AN2 noted in its prospectus that this approach is distinct from the earlier and failed monotherapy test of epetraborole. Promoted THE LATEST EVENTS IN THE EXCITING WORLD OF PRECISION MEDICINE AND HEALTH-TECH INNOVATIONS From May 24-25, come learn about the latest developments and investments in the world of precision medicine and health-teach innovations in these exciting new events in Dubai! PrecisionMed Exhibition & Summit | Emerge GHI AN2 launched in 2019 with a $12 million Series A round of funding and an agreement with Brii Biosciences, which licensed rights to develop the biotech’s lead antibacterial program in China. That deal did not come with an upfront payment, but AN2 is eligible to receive up to $15 million in regulatory milestones for each licensed product and up to $150 million in commercial milestones for each licensed product, according to the IPO filing. If a drug or drugs reach the Chinese market, AN2 is eligible to receive royalties from its partners sales of the products. AN2 closed an $80 million Series B financing round last year. The company’s largest shareholder is Adjuvant Global Health Technology Fund, which owns 17.2% of the biotech, followed by RA Capital Management’s 14.2% stake, according to the prospectus. With the IPO cash, AN2 plans to spend about $65 on clinical development of epetraborole for NTM lung disease that has resisted earlier lines of treatment. A Phase 1 renal impairment study is already underway; a placebo-controlled Phase 2/3 test is set to begin in the first half of this year. According to the prospectus, 80 patients will be enrolled in the Phase 2 portion of the study, which is not powered for statistical significance but will evaluate the safety, efficacy, and pharmacokinetics of the drug—in combination with standard of care treatments—compared to a placebo. The Phase 3 portion will enroll about 234 patients. AN2 is still working with the FDA to finalize the plan for this part of the study, but the company said in the IPO filing that it expects the main goal will be to test whether epetraborole, combined with two or more standard treatments, is superior to a placebo plus standard treatments. AN2 expects to post preliminary results from the Phase 2 portion of the study expected by the middle of next year. Another $5 million of the IPO proceeds is earmarked for expanding epetraborole to other geographic markets, initially Japan. The company also plans to develop the drug for other lung disorders caused by mycobacteria. Photo: Getty Images 0Shares TOPICS AN2 Therapeutics, antibiotic, biopharma nl, biotech IPO, California, Clinical Trials, epetraborole, menlo park, Pfizer HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER. We will never sell or share your information without your consent. See our privacy policy. Promoted 6 QUESTIONS FOR INVESTOR BRAEDEN LICHTI Braeden Lichti, a Canadian investor and co-founder of a private investment firm, talks about how he got his start on several of his healthcare companies. Sheeva Azma, on behalf of BWL Investments MEDCITY INVEST 2022 JOIN US AT MEDCITY INVEST 2022 MedCity INVEST, held March 28-30, 2022 at the Ritz-Carlton Chicago, is the premier national healthcare investing conference based in the Midwest, uniting active investors with corporate business development executives to facilitate investment opportunities with the most promising healthcare startups. Reserve your spot now.>> GOT NEWS? SEND US A TIP MEDCITY >> INBOX Get the latest industry news first when you subscribe to our newsletter. We will never sell or share your information without your consent. See our privacy policy. Promoted HOW MEDTECH CAN BETTER INTEGRATE WITH HEALTHCARE WORKFLOWS THROUGH DIGITAL SOLUTIONS Healthcare industry is transitioning to value-based care models. That’s why the medical device industry's ability to continue the development of life-changing innovations will rely on demonstrating how new technology fits under this value-based paradigm. To build future-ready solutions, it’s important to focus on choosing the right tools and technology partners. The Innovaccer Health Cloud is well-positioned to do just that! Innovaccer's Rishav Krishna & Smriti Khera × HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER. No thanks We will never sell or share your information without your consent. See our privacy policy. Advertise About Newsletter Our Sites * * * * * * * © 2022 Breaking Media, Inc. All rights reserved. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Privacy Center | Do not sell my information 0Shares WELCOME TO MEDCITYNEWS MEDCITYNEWS ASKS FOR YOUR CONSENT TO USE YOUR PERSONAL DATA TO: * perm_identity Personalised ads and content, ad and content measurement, audience insights and product development * devices Store and/or access information on a device expand_moreremove Learn more * How can I change my choice? * What if I don't consent? * How does legitimate interest work? * Do I have to consent to everything? Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with third party vendors, or used specifically by this site or app. Some vendors may process your personal data on the basis of legitimate interest, which you can object to by managing your options below. Look for a link at the bottom of this page or in our privacy policy where you can withdraw consent. Consent Manage options arrow_back Data preferences MANAGE YOUR DATA You can choose how your personal data is used. Vendors want your permission to do the following: TCF vendors help_outline STORE AND/OR ACCESS INFORMATION ON A DEVICE Cookies, device identifiers, or other information can be stored or accessed on your device for the purposes presented to you. View details Consent SELECT BASIC ADS Ads can be shown to you based on the content you’re viewing, the app you’re using, your approximate location, or your device type. View details ConsentLegitimate interesthelp_outline CREATE A PERSONALISED ADS PROFILE A profile can be built about you and your interests to show you personalised ads that are relevant to you. View details ConsentLegitimate interesthelp_outline SELECT PERSONALISED ADS Personalised ads can be shown to you based on a profile about you. View details ConsentLegitimate interesthelp_outline CREATE A PERSONALISED CONTENT PROFILE A profile can be built about you and your interests to show you personalised content that is relevant to you. View details ConsentLegitimate interesthelp_outline SELECT PERSONALISED CONTENT Personalised content can be shown to you based on a profile about you. View details ConsentLegitimate interesthelp_outline MEASURE AD PERFORMANCE The performance and effectiveness of ads that you see or interact with can be measured. View details ConsentLegitimate interesthelp_outline MEASURE CONTENT PERFORMANCE The performance and effectiveness of content that you see or interact with can be measured. View details ConsentLegitimate interesthelp_outline APPLY MARKET RESEARCH TO GENERATE AUDIENCE INSIGHTS Market research can be used to learn more about the audiences who visit sites/apps and view ads. View details ConsentLegitimate interesthelp_outline DEVELOP AND IMPROVE PRODUCTS Your data can be used to improve existing systems and software, and to develop new products View details ConsentLegitimate interesthelp_outline ENSURE SECURITY, PREVENT FRAUD, AND DEBUG help_outline Your data can be used to monitor for and prevent fraudulent activity, and ensure systems and processes work properly and securely. View details TECHNICALLY DELIVER ADS OR CONTENT help_outline Your device can receive and send information that allows you to see and interact with ads and content. View details MATCH AND COMBINE OFFLINE DATA SOURCES help_outline Data from offline data sources can be combined with your online activity in support of one or more purposes View details LINK DIFFERENT DEVICES help_outline Different devices can be determined as belonging to you or your household in support of one or more of purposes. View details RECEIVE AND USE AUTOMATICALLY-SENT DEVICE CHARACTERISTICS FOR IDENTIFICATION help_outline Your device might be distinguished from other devices based on information it automatically sends, such as IP address or browser type. View details USE PRECISE GEOLOCATION DATA Your precise geolocation data can be used in support of one or more purposes. This means your location can be accurate to within several meters. View details Consent Vendor preferences Accept all Confirm choices arrow_back Vendor preferences CONFIRM OUR VENDORS Vendors can use your data to provide services. Declining a vendor can stop them from using the data you shared. TCF vendors help_outline EXPONENTIAL INTERACTIVE, INC D/B/A VDX.TV Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ROQ.AD INC. Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent INDEX EXCHANGE, INC. Cookie duration: 395 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline QUANTCAST INTERNATIONAL LIMITED Cookie duration: 397 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BEESWAXIO CORPORATION Cookie duration: 395 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SOVRN HOLDINGS INC Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADIKTEEV Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline RTB HOUSE S.A. Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline WIDESPACE AB Cookie duration: 372 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent THE TRADE DESK Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADMETRICS GMBH Doesn't use cookies. View details | Privacy policylaunch Consent AMOBEE INC. Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EPSILON Cookie duration: 400 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline YAHOO EMEA LIMITED Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADVENTORI SAS Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TRIPLELIFT, INC. Cookie duration: 90 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline XANDR, INC. Cookie duration: 90 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEORY GMBH Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline UNRULY GROUP LLC Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEURAL.ONE Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADITION TECHNOLOGIES GMBH Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ACTIVE AGENT (ADITION TECHNOLOGIES GMBH) Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TABOOLA EUROPE LIMITED Cookie duration: 366 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMART ADSERVER Cookie duration: 396 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADFORM Cookie duration: 60 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAGNITE, INC. Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADARA MEDIA UNLIMITED Cookie duration: 730 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIFT MEDIA, INC Doesn't use cookies. View details | Privacy policylaunch Consent RAKUTEN MARKETING LLC Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AVOCET SYSTEMS LIMITED Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIFESTREET CORPORATION Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIZMEK BY AMAZON Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline OPENX Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline YIELDLAB AG Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ROKU ADVERTISING SERVICES Cookie duration: 731 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NANO INTERACTIVE GMBH Cookie duration: 182 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIMPLIFI HOLDINGS INC Cookie duration: 366 (days). View details | Privacy policylaunch Consent PUBMATIC, INC. Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline COMSCORE B.V. Cookie duration: 720 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline FLASHTALKING, INC. Cookie duration: 730 (days). View details | Privacy policylaunch Consent MEDIAMATH, INC. Cookie duration: 393 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMAATO, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SEMASIO GMBH Cookie duration: 366 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent CRIMTAN HOLDINGS LIMITED Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SCENE STEALER LIMITED Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BETGENIUS LTD Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TRESENSA TECHNOLOGIES, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CRITEO SA Cookie duration: 390 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADLOOX SA Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BLIS MEDIA LIMITED Cookie duration: 400 (days). Cookie duration resets each session. Uses other forms of storage. View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOTAME SOLUTIONS, INC Cookie duration: 274 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIVERAMP, INC. Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GROUPM UK LIMITED Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOOPME LIMITED Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DYNATA LLC Cookie duration: 365 (days). View details | Privacy policylaunch Consent FUSIO BY S4M Cookie duration: 1 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TEEMO SA Cookie duration: 30 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DOUBLEVERIFY INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BIDSWITCH GMBH Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IPONWEB GMBH Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEXTROLL, INC. Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TEADS Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline STRÖER SSP GMBH (SSP) Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline STRÖER SSP GMBH (DSP) Cookie duration: 90 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PLATFORM161 B.V. Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADACADO TECHNOLOGIES INC. (DBA ADACADO) Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MEETRICS GMBH Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMADEX, S.L.U. Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BOMBORA INC. Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SPOTX, INC Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EASYMEDIA GMBH Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent REMERGE GMBH Doesn't use cookies. View details | Privacy policylaunch Consent ADVANCED STORE GMBH Cookie duration: 24856 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAGNITE CTV, INC. Cookie duration: 366 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SPOTAD Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DELTA PROJECTS AB Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline USEMAX ADVERTISEMENT (EMEGO GMBH) Cookie duration: 365 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline EMETRIQ GMBH Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PUBLICIS MEDIA GMBH Cookie duration: 1827 (days). Uses other forms of storage. View details | Privacy policylaunch Consent MCCANN DISCIPLINE LTD Cookie duration: 14 (days). View details | Privacy policylaunch Consent ONETAG LIMITED Cookie duration: 741 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CLOUD TECHNOLOGIES S.A. Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMARTOLOGY LIMITED Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IMPROVE DIGITAL Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADOBE ADVERTISING CLOUD Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BANNERFLOW AB Cookie duration: 366 (days). View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline TABMO SAS Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline INTEGRAL AD SCIENCE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline WIZALY Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent WEBORAMA Cookie duration: 393 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline JIVOX CORPORATION Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MOBILE PROFESSIONALS BV Cookie duration: Uses session cookies. View details | Privacy policylaunch Consent ON DEVICE RESEARCH LIMITED Cookie duration: 30 (days). View details | Privacy policylaunch Consent EXACTAG GMBH Cookie duration: 180 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CELTRA, INC. Doesn't use cookies. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAINADV SRL Cookie duration: 1 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GEMIUS SA Cookie duration: 395 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent THE KANTAR GROUP LIMITED Cookie duration: 914 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IMPACT TECH INC. Cookie duration: 720 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NIELSEN MARKETING CLOUD Cookie duration: 120 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SOLOCAL Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PIXALATE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ORACLE DATA CLOUD Cookie duration: 180 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NUMBERLY Cookie duration: 396 (days). View details | Privacy policylaunch Consent AUDIENCEPROJECT APS Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EFFILIATION / EFFINITY Cookie duration: 60 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ARRIVALIST CO Cookie duration: 730 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SEENTHIS AB Doesn't use cookies. View details | Privacy policylaunch COMMANDERS ACT Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch Consent TRAVEL AUDIENCE GMBH Cookie duration: 397 (days). View details | Storage details | Privacy policylaunch Consent HUMAN Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADLUDIO LTD. Doesn't use cookies. View details | Privacy policylaunch Consent NEODATA GROUP SRL Cookie duration: 366 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline INNOVID INC. Cookie duration: 92 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TACTIC™ REAL-TIME MARKETING AS Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEUSTAR, INC. Cookie duration: 3650 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SUBLIMESKINZ - ADLEDGE Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SALESFORCE.COM, INC. Cookie duration: 180 (days). Uses other forms of storage. View details | Privacy policylaunch Consent VERVE GROUP EUROPE GMBH Doesn't use cookies. View details | Privacy policylaunch Consent KOCHAVA INC. Doesn't use cookies. View details | Privacy policylaunch Consent OTTO (GMBH & CO KG) Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADOBE AUDIENCE MANAGER, ADOBE EXPERIENCE PLATFORM Cookie duration: 180 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOCALSENSOR B.V. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ONLINE SOLUTION Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline RELAY42 NETHERLANDS B.V. Cookie duration: 731 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GP ONE GMBH Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIFTOFF MOBILE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MINDTAKE RESEARCH GMBH Cookie duration: 93 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AAX LLC Cookie duration: 2191 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CINT AB Cookie duration: 730 (days). View details | Privacy policylaunch Consent GOOGLE ADVERTISING PRODUCTS Cookie duration: 396 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GFK SE Cookie duration: 730 (days). Uses other forms of storage. View details | Privacy policylaunch Consent REVJET Cookie duration: 730 (days). View details | Privacy policylaunch Consent DIGISEG APS Doesn't use cookies. View details | Privacy policylaunch Consent PROTECTED MEDIA LTD Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CLINCH LABS LTD Cookie duration: 730 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline HEARTS & SCIENCE MÜNCHEN GMBH Cookie duration: 60 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AMAZON ADVERTISING Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MOLOCO, INC. Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline OBJECTIVE PARTNERS BV Cookie duration: 90 (days). View details | Privacy policylaunch Consent EBAY INC Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline General vendors help_outline GSKINNER Privacy policylaunch Consent AKAMAI Privacy policylaunch Consent FACEBOOK Privacy policylaunch Consent AUNICA Privacy policylaunch Consent BOOKING.COM Privacy policylaunch Consent C3 METRICS Privacy policylaunch Consent IBM Privacy policylaunch Consent ADTRIBA Privacy policylaunch Consent PULSEPOINT Privacy policylaunch Consent DEMANDBASE Privacy policylaunch Consent EVIDON Privacy policylaunch Consent CUBED Privacy policylaunch Consent HURRA.COM Privacy policylaunch Consent OPTOMATON Privacy policylaunch Consent INTELLIAD Privacy policylaunch Consent ANALIGHTS Privacy policylaunch Consent DSTILLERY Privacy policylaunch Consent DMA INSTITUTE Privacy policylaunch Consent ZMS Privacy policylaunch Consent DENTSU AEGIS NETWORK Privacy policylaunch Consent IGNITION ONE Privacy policylaunch Consent OMNICOM MEDIA GROUP Privacy policylaunch Consent RESONATE Privacy policylaunch Consent CENTRO Privacy policylaunch Consent SOJERN Privacy policylaunch Consent HAENSEL AMS Privacy policylaunch Consent BDSK HANDELS GMBH & CO. KG Privacy policylaunch Consent VIDEOLOGY Privacy policylaunch Consent TRADEDOUBLER AB Privacy policylaunch Consent TRUSTARC Privacy policylaunch Consent TRUEFFECT Privacy policylaunch Consent MARKETING SCIENCE CONSULTING GROUP, INC. Privacy policylaunch Consent DENTSU Privacy policylaunch Consent ESSENS Privacy policylaunch Consent TRAVEL DATA COLLECTIVE Privacy policylaunch Consent ADVOLUTION.CONTROL Privacy policylaunch Consent VIMEO Privacy policylaunch Consent ENSIGHTEN Privacy policylaunch Consent ADMAXIM Privacy policylaunch Consent BATCH MEDIA Privacy policylaunch Consent VODAFONE GMBH Privacy policylaunch Consent NETQUEST Privacy policylaunch Consent MANAGE.COM Privacy policylaunch Consent CLOUDFLARE Privacy policylaunch Consent SCOOTA Privacy policylaunch Consent HAVAS MEDIA FRANCE - DBI Privacy policylaunch Consent NETFLIX Privacy policylaunch Consent MACROMILL GROUP Privacy policylaunch Consent EBUILDERS Privacy policylaunch Consent APPLOVIN CORP. Privacy policylaunch Consent FRACTIONAL MEDIA Privacy policylaunch Consent RACKSPACE Privacy policylaunch Consent MSI-ACI Privacy policylaunch Consent NAVEGG Privacy policylaunch Consent ADMEDO Privacy policylaunch Consent MOBITRANS Privacy policylaunch Consent ADEX Privacy policylaunch Consent AARKI Privacy policylaunch Consent SFR Privacy policylaunch Consent CABLATO Privacy policylaunch Consent WAYSTACK Privacy policylaunch Consent Accept all Confirm choices Close Share this Article Friend's Email Address Your Name Your Email Address Comments Send Email Email sent! ×